In this edition:
Lipid lowering effects of obicetrapib with high-intensity statin
HDL-C levels and adverse CV outcomes
Coronary plaques, LDL-C levels and CVD events
LDL-C and CV and renal outcomes in moderate CKD
Lipoprotein(a), DAPT and outcomes after drug-eluting stent
Bempedoic acid for patients not receiving statins
Attainment of LDL-C goals with combination therapy
Lipoprotein(a) in ASCVD and aortic stenosis
Lipoprotein(a) levels in a global population
Pharmacotherapy in type 2 diabetes and ASCVD
Attainment of lipid targets following CABG surgery
Association of lipoprotein(a) with atherosclerotic plaque progression
Early statin therapy in ACS patients
Moderate-intensity statin + ezetimibe vs high-intensity statin in ASCVD
Protective effects of statins on COVID-19
Please login below to download this issue (PDF)